ID: ALA3957478

Max Phase: Preclinical

Molecular Formula: C26H26ClFN4O3

Molecular Weight: 496.97

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1c(F)c(N)cc(C(=O)Nc2cc(C(=O)Oc3ccccc3)ccc2N2CCN(C)CC2)c1Cl

Standard InChI:  InChI=1S/C26H26ClFN4O3/c1-16-23(27)19(15-20(29)24(16)28)25(33)30-21-14-17(26(34)35-18-6-4-3-5-7-18)8-9-22(21)32-12-10-31(2)11-13-32/h3-9,14-15H,10-13,29H2,1-2H3,(H,30,33)

Standard InChI Key:  VKUIARDCYFJGLG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 496.97

Molecular Weight (Monoisotopic): 496.1677

AlogP: 4.59

#Rotatable Bonds: 5

Polar Surface Area: 87.90

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.44

CX LogP: 5.11

CX LogD: 4.79

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.30

Np Likeness Score: -1.30

References

1. Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK..  (2016)  Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.,  24  (22): [PMID:27720555] [10.1016/j.bmc.2016.09.073]

Source

Source(1):

• Scientific Literature